Street Calls of the Week
Investing.com - DocMorris AG ron Thursday eported a 9.5% increase in external revenue for the first nine months of 2025, reaching CHF 854.3 million, with third-quarter revenue growing 8.1% to CHF 282.3 million despite seasonal slowdown during summer months.
The online pharmacy’s prescription (Rx) business showed accelerating sequential growth, with Rx revenue increasing by 9.2% from the second to the third quarter.
Overall, external Rx revenue rose significantly by 37.9% in the first nine months compared to the same period last year. Non-prescription (non-Rx) external revenue grew by 4.3% in the first nine months, with growth across all areas from Q2 to Q3.
The company’s telehealth service, TeleClinic, was a standout performer, increasing revenue by more than 140% to over CHF 17 million in the first nine months. The service, recently named one of the "World’s Top HealthTech Companies 2025" by TIME Magazine, is becoming an increasingly important part of DocMorris’ German business.
"Our continuous growth shows that we are on the right track with marketing efficiency in our core business and the scaling of innovative services," said CEO Walter Hess. The company has also fully rolled out its AI-based DocMorris health companion to all app users.
DocMorris confirmed its revenue and earnings guidance for 2025, maintaining its target of reaching EBITDA breakeven in the course of 2026 and free cash flow breakeven in the course of 2027.
The company reported that its active customer base increased from 10.3 million to 10.6 million in the first nine months of the year.
CFO Daniel Wüest noted, "DocMorris has made an encouraging start to what is traditionally its strongest fourth quarter. The figures for the first nine months confirm our growth trajectory."
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.